Small dose of rituximab for graves orbitopathy: New insights into the mechanism of action

Archives of Ophthalmology

Volumn 130, Issue 1, 2012, Pages 122-124

  Salvi, Mario ^a   Vannucchi, Guia ^a   Currò, Nicola ^b   Introna, Martino ^d   Rossi, Stefania ^c   Bonara, Paola ^b   Covelli, Danila ^a   Dazzi, Davide ^e   Guastella, Claudio ^b   Pignataro, Lorenzo ^b   Ratiglia, Roberto ^b   Golay, Josée ^d   Beck Peccoz, Paolo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e Ospedale di Fidenza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; HYDROCORTISONE SODIUM SUCCINATE; IODINE 131; LEVOTHYROXINE; RITUXIMAB; STEROID;

ADULT; AGED; ARTICLE; CASE REPORT; CD3+ T LYMPHOCYTE; CELL SUBPOPULATION; DISEASE ACTIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; ENDOCRINE OPHTHALMOPATHY; FEMALE; FLOW CYTOMETRY; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MYXEDEMA; PRIORITY JOURNAL; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIGENS, CD20; B-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MACROPHAGES; MALE; MIDDLE AGED; ORBITAL DISEASES;

EID: 84855568507     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopthalmol.2011.1215     Document Type: Article

References (5)

1. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev. 2008;223:284-299. (Pubitemid 351986191)
2. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156(1):33-40. (Pubitemid 46553901)
3. Khanna D, Chong KK, Afifiyan NF, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117(1):133-139, e2.
4. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) . 1997;47(1):9-14. (Pubitemid 27313981)
5. Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximabopsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009;182(7):4415-4422.